Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thomas Siudzinski

Physician Assistant Buffalo, NY Physician Assistant

NPI 1912436965 CMS profile 10740488

100 High St, Buffalo, NY 14203

Open in the dashboard

General payments

$4,319

191 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Siudzinski of Buffalo, NY is reported in the CMS Open Payments database as having received $4,319 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $975 54
2024 General $660 31
2023 General $659 28
2022 General $590 30
2021 General $1,435 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Siudzinski
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Thomas Siudzinski were reported at $975. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Thomas Siudzinski Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,435 $132 $37–$438 $132
2022 $590 $155 $48–$522 $149
2023 $659 $167 $52–$557 $160
2024 $660 $178 $55–$600 $164
2025 $975 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,320 46 payments
  2. Abbott Laboratories $568 15 payments
  3. E.R. Squibb & Sons, L.L.C. $330 22 payments
  4. Novartis Pharmaceuticals Corporation $283 19 payments
  5. Impulse Dynamics (USA) Inc. $220 4 payments
  6. Janssen Pharmaceuticals, Inc $217 13 payments
  7. Merck Sharp & Dohme Corporation $204 10 payments
  8. Pfizer Inc. $197 11 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $147 9 payments
  10. Edwards Lifesciences Corporation $142 5 payments
  11. Other $692 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,319 191 payments
Products named General payments · program years 2021–2025
  1. Assurity Pacemaker $435 10 payments
  2. EMBLEM $241 6 payments
  3. VERQUVO $229 11 payments
  4. OPTIMIZER Cardiovascular Device $220 4 payments
  5. OPTIMIZER Cardiovascular Device $220 4 payments
  6. LUX-Dx Insertable Cardiac Monitor $219 7 payments
  7. XARELTO $217 13 payments
  8. LUX DX Therapies $200 11 payments
  9. ELIQUIS $184 13 payments
  10. LUX DX Pain Management $175 3 payments
  11. Other $2,288 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,135

Median for Physician Assistant: 241

Drug cost

$724,862

Median for Physician Assistant: $4,110

Branded share of claims

39%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 364 $474,130
Xarelto Rivaroxaban Brand 125 $155,145
Dofetilide Generic 188 $47,320
Acebutolol Hcl Generic 158 $10,505
Flecainide Acetate Generic 146 $7,373
Metoprolol Succinate Generic 302 $6,737
Amiodarone Hcl Generic 176 $5,051
Sotalol Af Sotalol Hcl Brand 122 $4,384
Sotalol Sotalol Hcl Brand 122 $2,869
Mexiletine Hcl Generic 20 $2,832

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$21,217

Medicare's payments for the services billed

Medicare patients

256

Average age 74

Services billed

618

115 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 50%
Ischemic heart disease 46%
Arthritis 46%
Chronic kidney disease 38%
Diabetes 27%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $58
$58 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $42
  • Lilly USA, LLC $13
$55 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $32
  • PFIZER INC. $20
$52 364 —
VERQUVO
  • Merck Sharp & Dohme Corporation $45
$45 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record